SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

LongEveron Announces Updated Phase 2b Trial Results for Laromestrocel

LongEveron announced updated results from its Phase 2b ELPIS II clinical trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome.

LGVN

Related stories